comparemela.com
Home
Live Updates
Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS) : comparemela.com
Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies addressing...
Related Keywords
Poland
,
United States
,
France
,
Paris
,
France General
,
Germany
,
Warsaw
,
L67
,
Leipzig
,
Sachsen
,
French
,
German
,
Uwe Platzbecker
,
Pierre Fenaux
,
Hendrik Nogai
,
Department For Hematology
,
Linkedin
,
University Hospital Leipzig
,
Coordination Office
,
International Westa German Contract Research Organization
,
European Hematology Association Scientific Working Group
,
Menarini Group
,
Twitter
,
Ryvu Development
,
Warsaw Stock Exchange
,
Clinical Trial Financial Support
,
Saint Louis
,
Low Risk Myelodysplastic Syndromes
,
Service International
,
Coordinating Principal Investigator
,
Development Plans
,
Chief Medical Officer
,
Ryvu Therapeutics
,
Professor Uwe Platzbecker
,
Professor Platzbecker
,
Service International West
,
German Contract Research Organization
,
Cellular Therapy
,
Infectious Diseases
,
Acute Myeloid Leukemia
,
Health Care Amp Hospitals
,
Medical Pharmaceuticals
,
Pharmaceuticals
,
Biotechnology
,
Clinical Trials Amp Medical Discoveries
,
comparemela.com © 2020. All Rights Reserved.